Tuesday, August 18, 2026
ExploreSearch
Finance Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,812
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,812 facts checked against source5,219 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 30, 2026

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility

View original at finance.yahoo.com
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide Company plans to create more than 2,800 manufacturing and construction jobs at Lilly's 10th U.S…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Having modern, robust pharmaceutical manufacturing capabilities here in the United States is essential for both our national security and domestic economy

    80% confidence

  • This multi-billion dollar investment in the Lehigh Valley is a powerful testament to Pennsylvania's leadership in life sciences and advanced manufacturing

    80% confidence

  • For each manufacturing job created, several more will be generated in related sectors like supply chain, logistics and retail

    80% confidence

  • When we announced our Economic Development Strategy here in the Lehigh Valley two years ago, we set out to win historic, life-changing deals like the one we're announcing with Lilly today. Before I took office, Pennsylvania wasn't even in the conversation for major investments like this

    80% confidence

  • Our mission starts with patients and delivering the medicines they need. To meet increasing demand, we're expanding our U.S. manufacturing network, with Lehigh Valley adding capacity for next‑generation weight-loss medicines

    80% confidence

  • For every dollar Lilly invests, it estimates up to four dollars in additional local economic activity

    80% confidence

  • Pennsylvania continues to be a leader in health care innovation, and I will always support companies like Lilly making major investments to advance these technologies

    80% confidence

  • Lilly Lehigh Valley—our newest injectable medicine and device manufacturing facility—will increase access to next-generation weight-loss treatments and improve the domestic supply of essential medicines for current and future patients

    80% confidence

Cited in these Via News reports